These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 31436331)
1. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. Wang F; Gao X; Chen X; Tang X; Chen H; Han J J Dermatol; 2019 Nov; 46(11):1035-1038. PubMed ID: 31436331 [TBL] [Abstract][Full Text] [Related]
2. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Wang R; Zhong S; Tu P; Li R; Wang M Dermatol Ther; 2019 Jul; 32(4):e12832. PubMed ID: 30659711 [TBL] [Abstract][Full Text] [Related]
3. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential. So N; Leavitt E; Aleshin M; Worswick S Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438 [TBL] [Abstract][Full Text] [Related]
4. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept. Gavigan GM; Kanigsberg ND; Ramien ML J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925 [TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report. Chong I; Chao A Perm J; 2017; 21():16-060. PubMed ID: 28488978 [TBL] [Abstract][Full Text] [Related]
6. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Schneider JA; Cohen PR Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study. Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514 [TBL] [Abstract][Full Text] [Related]
8. Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. Gao X; Tang X; Ai L; Gao Q; Liao Q; Chen M; Chen X; Zhou H; Ye Y; Li M; Han J; Wang F J Am Acad Dermatol; 2021 Mar; 84(3):644-653. PubMed ID: 32561372 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Dreyer SD; Torres J; Stoddard M; Leavitt E; Sutton A; Aleshin M; Crew A; Worswick S Cutis; 2021 Jun; 107(6):E22-E28. PubMed ID: 34314327 [TBL] [Abstract][Full Text] [Related]
10. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis. Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158 [TBL] [Abstract][Full Text] [Related]
11. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Tian CC; Ai XC; Ma JC; Hu FQ; Liu XT; Luo YJ; Tan GZ; Zhang JM; Li XQ; Guo Q; Zeng FQ; Shi ZR; Wang L Ann Allergy Asthma Immunol; 2022 Sep; 129(3):360-365.e1. PubMed ID: 35598882 [TBL] [Abstract][Full Text] [Related]
12. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Tan SK; Tay YK Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study. He CX; Guo L; Qu T; Jin HZ Front Immunol; 2024; 15():1421684. PubMed ID: 39170619 [TBL] [Abstract][Full Text] [Related]
15. Biologic TNF-α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis. Cao J; Zhang X; Xing X; Fan J Dermatol Ther (Heidelb); 2023 Jun; 13(6):1305-1327. PubMed ID: 37178320 [TBL] [Abstract][Full Text] [Related]
16. Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Report and Literature Review. Meledathu S; Gordon M; Thornton M; Ashinoff R J Drugs Dermatol; 2023 Nov; 22(11):e24-e28. PubMed ID: 37943271 [TBL] [Abstract][Full Text] [Related]
17. Severe pneumonia caused by combined infection with Pneumocystis jiroveci, parainfluenza virus type 3, cytomegalovirus, and Aspergillus fumigatus in a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis. Lee T; Bae YJ; Park SK; Park HJ; Kim SH; Cho YS; Moon HB; Lee SO; Kim TB Acta Derm Venereol; 2010 Nov; 90(6):625-9. PubMed ID: 21057748 [TBL] [Abstract][Full Text] [Related]
18. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432 [TBL] [Abstract][Full Text] [Related]
19. Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Treated Successfully with Oral Cyclosporin: Case report and literature review. Al Rajaibi R; Al Rumhi T; Al Abri AM Sultan Qaboos Univ Med J; 2021 Aug; 21(3):491-494. PubMed ID: 34522420 [TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]